<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastric Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Gastric Cancer</journal-id><journal-title-group><journal-title>Gastric Cancer</journal-title></journal-title-group><issn pub-type="ppub">1436-3291</issn><issn pub-type="epub">1436-3305</issn><publisher><publisher-name>Springer Japan</publisher-name><publisher-loc>Tokyo</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25185971</article-id><article-id pub-id-type="pmc">4572054</article-id><article-id pub-id-type="publisher-id">420</article-id><article-id pub-id-type="doi">10.1007/s10120-014-0420-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Satoh</surname><given-names>Taroh</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Kyung Hee</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Rha</surname><given-names>Sun Young</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Sasaki</surname><given-names>Yasutsuna</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Se Hoon</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Komatsu</surname><given-names>Yoshito</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Yasui</surname><given-names>Hirofumi</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Tae-You</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Yamaguchi</surname><given-names>Kensei</given-names></name><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Fuse</surname><given-names>Nozomu</given-names></name><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Yamada</surname><given-names>Yasuhide</given-names></name><xref ref-type="aff" rid="Aff11"/></contrib><contrib contrib-type="author"><name><surname>Ura</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="Aff12"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Si-Young</given-names></name><xref ref-type="aff" rid="Aff13"/></contrib><contrib contrib-type="author"><name><surname>Munakata</surname><given-names>Masaki</given-names></name><xref ref-type="aff" rid="Aff14"/></contrib><contrib contrib-type="author"><name><surname>Saitoh</surname><given-names>Soh</given-names></name><xref ref-type="aff" rid="Aff15"/></contrib><contrib contrib-type="author"><name><surname>Nishio</surname><given-names>Kazuto</given-names></name><xref ref-type="aff" rid="Aff16"/></contrib><contrib contrib-type="author"><name><surname>Morita</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="Aff17"/></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Eriko</given-names></name><xref ref-type="aff" rid="Aff18"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Qingwei</given-names></name><xref ref-type="aff" rid="Aff19"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jung-mi</given-names></name><xref ref-type="aff" rid="Aff20"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kim</surname><given-names>Yeul Hong</given-names></name><address><phone>+82-2-9205569</phone><email>yhk0215@korea.ac.kr</email></address><xref ref-type="aff" rid="Aff21"/></contrib><contrib contrib-type="author"><name><surname>Sakata</surname><given-names>Yuh</given-names></name><xref ref-type="aff" rid="Aff14"/></contrib><aff id="Aff1"><label/>Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan </aff><aff id="Aff2"><label/>Hemato-Oncology, Internal Medicine, Yeungnam University Hospital, Daegu, Republic of Korea </aff><aff id="Aff3"><label/>Medical Oncology, Internal Medicine, Yonsei Cancer Center, Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea </aff><aff id="Aff4"><label/>Medical Oncology, Saitama Medical University International Medical Center, Saitama, Japan </aff><aff id="Aff5"><label/>Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University Samsung Medical Center, Seoul, Republic of Korea </aff><aff id="Aff6"><label/>Division of Cancer Chemotherapy, Hokkaido University Hospital, Hokkaido, Japan </aff><aff id="Aff7"><label/>Division of GI Oncology, Shizuoka Cancer Center, Shizuoka, Japan </aff><aff id="Aff8"><label/>Hematology-Oncology, Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea </aff><aff id="Aff9"><label/>Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan </aff><aff id="Aff10"><label/>Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan </aff><aff id="Aff11"><label/>Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan </aff><aff id="Aff12"><label/>Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan </aff><aff id="Aff13"><label/>Department of Medical Oncology and Hematology, Kyung Hee University Hospital, Seoul, Republic of Korea </aff><aff id="Aff14"><label/>Internal Medicine, Misawa Municipal Hospital, Aomori, Japan </aff><aff id="Aff15"><label/>Medical Oncology and Gastroenterology, Aomori Prefectural Central Hospital, Aomori, Japan </aff><aff id="Aff16"><label/>Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan </aff><aff id="Aff17"><label/>Department of Biostatics and Epidemiology, Yokohama City University, Kanagawa, Japan </aff><aff id="Aff18"><label/>Clinical Development Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan </aff><aff id="Aff19"><label/>Clinical Data and Biostatistics Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan </aff><aff id="Aff20"><label/>Medical and Regulatory Affairs Department, Kuhnil Pharm. Co., Ltd., Seoul, Republic of Korea </aff><aff id="Aff21"><label/>Department of Internal Medicine, Section of Hemato-Oncology, Korea University Anam Hospital, 126-1 Anam-dong 5ga, Seongbuk-gu, Seoul, 136-705 Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>18</volume><issue>4</issue><fpage>824</fpage><lpage>832</lpage><history><date date-type="received"><day>14</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone (IRI) in patients with advanced gastric cancer (AGC) showing disease progression after previous 5-fluorouracil-based therapy.</p></sec><sec><title>Methods</title><p>Irinotecan-naive patients (<italic>n</italic>&#x000a0;=&#x000a0;82) received N-IRI (nimotuzumab 400&#x000a0;mg weekly plus irinotecan 150&#x000a0;mg/m<sup>2</sup> biweekly) or IRI (irinotecan 150&#x000a0;mg/m<sup>2</sup> biweekly) until disease progression. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), response rate (RR), safety, tolerability, and the correlation between efficacy and tumor epidermal growth factor receptor (EGFR) expression.</p></sec><sec><title>Results</title><p>Of 83 patients, 40 and 43 patients were randomly assigned to the N-IRI and IRI groups, respectively. In the N-IRI/IRI treatment group, median PFS was 73.0/85.0&#x000a0;days (<italic>P</italic>&#x000a0;=&#x000a0;0.5668), and median OS and RR at 18&#x000a0;months were 250.5/232.0&#x000a0;days (<italic>P</italic>&#x000a0;=&#x000a0;0.9778) and 18.4/10.3&#x000a0;%, respectively. Median PFS and OS in the EGFR 2+/3+ subgroups were 118.5/59.0 and 358.5/229.5&#x000a0;days, respectively. The RR was 33.3/0.0&#x000a0;% in the N-IRI/IRI treatment group. The incidence of grade 3 or higher adverse events was 77.5/64.3&#x000a0;%. No adverse events of grade 3 or higher skin rash or grade 3 or higher infusion-related reaction were reported.</p></sec><sec><title>Conclusions</title><p>There was no superiority of N-IRI over IRI alone in terms of PFS in 5-fluorouracil-refractory AGC patients. However, N-IRI showed potential improvement in the EGFR 2+/3+ subgroup based on improved RR, PFS, and OS.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Nimotuzumab</kwd><kwd>Anti-EGFR</kwd><kwd>Irinotecan</kwd><kwd>Second-line therapy</kwd><kwd>Advanced gastric cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="intro"><title>Introduction</title><p>Patients with unresectable gastric cancer receiving the best supportive care have poor outcomes, with median survival times ranging from 3 to 5&#x000a0;months [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In the metastatic disease setting, palliative chemotherapy improves survival compared with supportive care alone, with combined drug therapy yielding the best results [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Although there is no universally accepted standard treatment for advanced gastric cancer (AGC), several combination regimens have been used as first-line treatment, including epirubicin&#x02013;oxaliplatin&#x02013;capecitabine [<xref ref-type="bibr" rid="CR4">4</xref>], cisplatin&#x02013;capecitabine [<xref ref-type="bibr" rid="CR5">5</xref>], cisplatin-S-1 [<xref ref-type="bibr" rid="CR6">6</xref>], cisplatin&#x02013;5-fluorouracil, and docetaxel&#x02013;cisplatin&#x02013;5-fluorouracil [<xref ref-type="bibr" rid="CR7">7</xref>]. However, the median survival has not exceeded 8&#x02013;13&#x000a0;months [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>], and second-line treatments need to be established. Irinotecan [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>] or paclitaxel monotherapy is commonly used for AGC patients as second-line treatment, especially in Japan and Korea. Because of the limitations of the current therapies, addition of molecular-targeted drugs, particularly to chemotherapies with acceptable toxicities, may improve the outcomes. The ToGA trial demonstrated that the addition of trastuzumab to standard chemotherapy in patients with human EGFR-2 (HER-2)-overexpressing tumors improved overall survival (OS) and progression-free survival (PFS) [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>Epidermal growth factor receptor (EGFR) is known to be expressed in a variety of tumors [<xref ref-type="bibr" rid="CR11">11</xref>]. Approximately 30&#x000a0;% of gastric cancers are reported to show EGFR overexpression [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. EGFR signaling pathways are frequently dysregulated in gastric cancer, thereby serving as attractive therapeutic targets.</p><p>Nimotuzumab, a recombinant humanized monoclonal immunoglobulin G<sub>1</sub> antibody against human EGFR (HER-1), blocks the binding of epidermal growth factor (EGF) and transforming growth factor-&#x003b1; to EGFR. This mechanism regulates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, inhibiting tumor cell growth and angiogenesis and inducing apoptosis [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. In a previous phase I study in Japan, the safety and tolerability of nimotuzumab were investigated up to 400&#x000a0;mg doses weekly [<xref ref-type="bibr" rid="CR18">18</xref>]. When combined with radiotherapy or chemoradiotherapy, nimotuzumab exerts clinical efficacy against head and neck cancers, gliomas, and non-small cell lung cancer (NSCLC) [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Additionally, because of the low frequency of severe dermatological toxicity, nimotuzumab is expected to improve the quality of life.</p><p>The present study was an open-label, phase II collaborative study between Japan and Korea. The primary objective was to compare PFS following combined nimotuzumab plus irinotecan therapy (N-IRI) and irinotecan monotherapy (IRI) in patients with unresectable or recurrent gastric cancer refractory to 5-fluorouracil-based therapy.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Patients</title><p>Patients in Japan and Korea were enrolled in this multicenter, open-label, randomized phase II trial. Patients with histologically confirmed AGC refractory to previous 5-fluorouracil-based chemotherapy for metastatic disease were eligible. Other major inclusion criteria were as follows: age of 20&#x02013;75&#x000a0;years; adequate organ function; and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1. Major exclusion criteria were prior exposure to irinotecan or EGFR-directed therapy, and significant comorbidities, such as diarrhea, interstitial pneumonia, or pulmonary fibrosis.</p><p>The trial was conducted in accordance with the Declaration of Helsinki. All the patients provided written informed consent. The institutional review boards or ethics committees of all participating centers reviewed and approved the protocol.</p></sec><sec id="Sec4"><title>Study treatment</title><p>Patients were randomly assigned at a ratio of 1:1 to the N-IRI or IRI group by a computer program on the basis of the resection status of the primary tumor (inoperable advanced/postoperative recurrent) and study site, using the random permuted blocks method. Neither the patients nor the investigators were blinded to the treatment assignment.</p><p>Nimotuzumab (400&#x000a0;mg) diluted in normal saline to a total volume of 250&#x000a0;ml was administered once weekly by intravenous infusion over 30&#x000a0;min. Irinotecan (150&#x000a0;mg/m<sup>2</sup>) was administered every 2&#x000a0;weeks. Treatment was continued until disease progression, appearance of unacceptable toxicity, or withdrawal of consent.</p></sec><sec id="Sec5"><title>Efficacy and safety assessments</title><p>The primary endpoint was PFS following N-IRI versus IRI treatment. PFS was defined as the time from randomization to the day of documentation of progression or death, whichever was earlier. The secondary endpoints were OS, response rate (RR), disease control rate (DCR), safety, and tolerability. Tumor assessment by computed tomography was performed at baseline, and then every 4&#x000a0;weeks for the first 16&#x000a0;weeks, and every 6&#x000a0;weeks thereafter. Evaluation of tumors was performed by an independent Efficacy Evaluation Committee using RECIST 1.0. Adverse events were assessed according to the National Cancer Institute&#x02019;s Common Terminology Criteria for Adverse Events, version 3.0.</p></sec><sec id="Sec6"><title>Exploratory biomarker analysis</title><p>EGFR protein expression levels, <italic>EGFR</italic> gene amplification status, <italic>K-ras</italic> mutations, and HER-2 protein expression levels were measured in tissue specimens from tumors obtained from patients who had provided informed consent for exploratory biomarker analysis. The tumor tissues were centrally tested and classified. EGFR expression was analyzed using an immunohistochemistry (IHC) staining kit (EGFR PharmDX; Dako, Copenhagen, Denmark) and classified into four categories (0, 1+, 2+, and 3+), as previously described [<xref ref-type="bibr" rid="CR21">21</xref>]. The <italic>EGFR</italic> gene copy number was measured by fluorescence in situ hybridization (FISH), as reported previously [<xref ref-type="bibr" rid="CR22">22</xref>]. For <italic>K-ras</italic> mutation analysis, DNA was extracted from formalin-fixed paraffin-embedded tumor samples. The sequences of <italic>K-ras</italic> codons 12 and 13 and the surrounding region of the gene were analyzed by conventional polymerase chain reaction followed by direct sequencing. The expression status of HER-2 was analyzed using the HercepTest kit (Dako) and classified into four categories (0, 1+, 2+, and 3+).</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>The reported median PFS in AGC patients treated with irinotecan or paclitaxel as second-line chemotherapy is 2.1&#x02013;2.6&#x000a0;months [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. For an exploratory study, if the median PFS times for N-IRI and IRI therapy are assumed to be 4.5 and 2.5&#x000a0;months, respectively, then 32 patients per treatment arm would be required to detect a difference with 80&#x000a0;% power at a 10&#x000a0;% significance level using a one-sided log-rank test of the equality of survival curves. Assuming a dropout rate of 20&#x000a0;%, the number of patients per treatment group was set at 40, with a total sample size of at least 80 patients. The median PFS was calculated with the 95&#x000a0;% confidence interval (CI) for both treatment groups. Log-rank tests were performed to evaluate differences in PFS with the significance level set at 10&#x000a0;% (one sided). Primary statistical analysis of the efficacy endpoint was performed 6&#x000a0;months after registration of the last patient for the study.</p><p>For subgroup analyses of PFS and OS, the hazard ratio (HR) and 95&#x000a0;% CI within each subgroup were displayed in forest plots. In both treatment groups, the Kaplan&#x02013;Meier method was used to plot the survival curves and estimate the cumulative incidence from the day of registration to death, as well as the cumulative incidence to disease progression. For evaluation of efficacy, point estimates were calculated for the RR and DCR and compared using the chi-squared test. Efficacy endpoints were analyzed using the full analysis set, safety endpoints were analyzed using the safety analysis set, and pharmacokinetic analyses were performed using the pharmacokinetic analysis set.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Patients</title><p>A total of 83 patients were randomized from September 2008 to December 2009. Of these patients, 82 were included in the safety and efficacy analysis population (1 patient from the IRI group did not have a target lesion and did not receive irinotecan; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). At the 18-month follow-up after registration of the last patient for the study, the median nimotuzumab and irinotecan exposure in the N-IRI group was 71.5&#x000a0;days (range, 8&#x02013;947) and 60.5&#x000a0;days (range, 1&#x02013;268), respectively, and the median irinotecan exposure in the IRI group was 57.0&#x000a0;days (range, 1&#x02013;953). The median follow-up period was 242.5&#x000a0;days (range, 22&#x02013;955). Patient demographics, including the UGT1A1 subtype, were well matched between the two treatment groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). 
<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>CONSORT diagram. <italic>N-IRI</italic> nimotuzumab plus irinotecan, <italic>IRI</italic> irinotecan alone</p></caption><graphic xlink:href="10120_2014_420_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristics</th><th align="left" colspan="2">N-IRI arm (<italic>n</italic>&#x000a0;=&#x000a0;40)</th><th align="left" colspan="2">IRI arm (<italic>n</italic>&#x000a0;=&#x000a0;42)</th><th align="left" colspan="2">Total (<italic>n</italic>&#x000a0;=&#x000a0;82)</th></tr><tr><th align="left">
<italic>n</italic>
</th><th align="left">%</th><th align="left">
<italic>n</italic>
</th><th align="left">%</th><th align="left">
<italic>n</italic>
</th><th align="left">%</th></tr></thead><tbody><tr><td align="left" colspan="7">Age (years)</td></tr><tr><td align="left">&#x000a0;Median</td><td char="." align="left" colspan="2">60.0</td><td char="." align="left" colspan="2">63.5</td><td char="." align="left" colspan="2">61.5</td></tr><tr><td align="left">&#x000a0;Range</td><td align="left" colspan="2">27&#x02013;75</td><td align="left" colspan="2">32&#x02013;75</td><td align="left" colspan="2">27&#x02013;75</td></tr><tr><td align="left" colspan="7">Sex</td></tr><tr><td align="left">&#x000a0;Male</td><td char="." align="left">33</td><td char="." align="left">82.5</td><td char="." align="left">33</td><td char="." align="left">78.6</td><td char="." align="left">66</td><td char="." align="left">80.5</td></tr><tr><td align="left">&#x000a0;Female</td><td char="." align="left">7</td><td char="." align="left">17.5</td><td char="." align="left">9</td><td char="." align="left">21.4</td><td char="." align="left">16</td><td char="." align="left">19.5</td></tr><tr><td align="left" colspan="7">ECOG performance status</td></tr><tr><td align="left">&#x000a0;0</td><td char="." align="left">19</td><td char="." align="left">47.5</td><td char="." align="left">17</td><td char="." align="left">40.5</td><td char="." align="left">36</td><td char="." align="left">43.9</td></tr><tr><td align="left">&#x000a0;1</td><td char="." align="left">21</td><td char="." align="left">52.5</td><td char="." align="left">25</td><td char="." align="left">59.5</td><td char="." align="left">46</td><td char="." align="left">56.1</td></tr><tr><td align="left" colspan="7">Body weight (kg)</td></tr><tr><td align="left">&#x000a0;Median</td><td char="." align="left" colspan="2">56.3</td><td char="." align="left" colspan="2">54.2</td><td char="." align="left" colspan="2">56.0</td></tr><tr><td align="left">&#x000a0;Range</td><td align="left" colspan="2">42.0&#x02013;81.4</td><td align="left" colspan="2">37.5&#x02013;107.0</td><td align="left" colspan="2">37.5&#x02013;107.0</td></tr><tr><td align="left" colspan="7">Resection status of the primary tumor</td></tr><tr><td align="left">&#x000a0;Inoperable advanced</td><td char="." align="left">22</td><td char="." align="left">55.0</td><td char="." align="left">23</td><td char="." align="left">54.8</td><td char="." align="left">45</td><td char="." align="left">54.9</td></tr><tr><td align="left">&#x000a0;Postoperative recurrent</td><td char="." align="left">18</td><td char="." align="left">45.0</td><td char="." align="left">19</td><td char="." align="left">45.2</td><td char="." align="left">37</td><td char="." align="left">45.1</td></tr><tr><td align="left" colspan="7">Histological diagnosis, <italic>n</italic>
</td></tr><tr><td align="left">&#x000a0;Well/moderately differentiated adenocarcinoma</td><td char="." align="left">15</td><td char="." align="left">37.5</td><td char="." align="left">19</td><td char="." align="left">45.2</td><td char="." align="left">34</td><td char="." align="left">41.5</td></tr><tr><td align="left">&#x000a0;Poorly differentiated adenocarcinoma</td><td char="." align="left">21</td><td char="." align="left">52.5</td><td char="." align="left">17</td><td char="." align="left">40.5</td><td char="." align="left">38</td><td char="." align="left">46.3</td></tr><tr><td align="left">&#x000a0;Others</td><td char="." align="left">4</td><td char="." align="left">10.0</td><td char="." align="left">6</td><td char="." align="left">14.3</td><td char="." align="left">10</td><td char="." align="left">12.2</td></tr><tr><td align="left" colspan="7">Primary tumor site</td></tr><tr><td align="left">&#x000a0;Absent</td><td char="." align="left">18</td><td char="." align="left">45.0</td><td char="." align="left">16</td><td char="." align="left">38.1</td><td char="." align="left">34</td><td char="." align="left">41.5</td></tr><tr><td align="left">&#x000a0;Present</td><td char="." align="left">22</td><td char="." align="left">55.0</td><td char="." align="left">26</td><td char="." align="left">61.9</td><td char="." align="left">48</td><td char="." align="left">58.5</td></tr><tr><td align="left">&#x000a0;Gastroesophageal junction</td><td char="." align="left">4</td><td char="." align="left">18.2</td><td char="." align="left">1</td><td char="." align="left">3.8</td><td char="." align="left">5</td><td char="." align="left">10.4</td></tr><tr><td align="left">&#x000a0;Gastric region</td><td char="." align="left">18</td><td char="." align="left">81.8</td><td char="." align="left">25</td><td char="." align="left">96.2</td><td char="." align="left">43</td><td char="." align="left">89.6</td></tr><tr><td align="left" colspan="7">Metastatic focus site</td></tr><tr><td align="left">&#x000a0;No</td><td align="left">1</td><td align="left">2.5</td><td align="left">0</td><td align="left">0.0</td><td align="left">1</td><td align="left">1.2</td></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">39</td><td align="left">97.5</td><td align="left">42</td><td align="left">100.0</td><td align="left">81</td><td align="left">98.8</td></tr><tr><td align="left">&#x000a0;&#x000a0;Lymph node</td><td align="left">25</td><td align="left">64.1</td><td align="left">25</td><td align="left">59.5</td><td align="left">50</td><td align="left">61.7</td></tr><tr><td align="left">&#x000a0;&#x000a0;Liver</td><td align="left">13</td><td align="left">33.3</td><td align="left">19</td><td align="left">45.2</td><td align="left">32</td><td align="left">39.5</td></tr><tr><td align="left">&#x000a0;&#x000a0;Lung</td><td align="left">3</td><td align="left">7.7</td><td align="left">6</td><td align="left">14.3</td><td align="left">9</td><td align="left">11.1</td></tr><tr><td align="left">&#x000a0;&#x000a0;Other</td><td align="left">19</td><td align="left">48.7</td><td align="left">18</td><td align="left">42.9</td><td align="left">37</td><td align="left">45.7</td></tr><tr><td align="left" colspan="7">UGT1A1 gene polymorphism</td></tr><tr><td align="left">&#x000a0;*1/*1, *1/*6, *1/*28</td><td align="left">38</td><td align="left">95.0</td><td align="left">39</td><td align="left">92.9</td><td align="left">77</td><td align="left">93.9</td></tr><tr><td align="left">&#x000a0;*6/*6, *28/*28, *6/*28</td><td align="left">2</td><td align="left">5.0</td><td align="left">3</td><td align="left">7.1</td><td align="left">5</td><td align="left">6.1</td></tr></tbody></table><table-wrap-foot><p>
<italic>N-IRI</italic> nimotuzumab plus irinotecan, <italic>IRI</italic> irinotecan alone, <italic>n</italic> number of patients, <italic>ECOG</italic> Eastern Cooperative Oncology Group</p></table-wrap-foot></table-wrap></p><p>Of the 83 patients, 48 patients had provided informed consent for exploratory biomarker analysis and submitted tumor samples. The EGFR protein expression level was detected in the assessable tumor tissues of 47 patients (57.3&#x000a0;% of the full analysis set population) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). 
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>EGFR and HER-2 protein expression levels identified by immunohistochemistry</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="8">EGFR</th></tr><tr><th align="left" colspan="2">0</th><th align="left" colspan="2">1+</th><th align="left" colspan="2">2+, 3+</th><th align="left" colspan="2">Total</th></tr><tr><th align="left">
<italic>n</italic>
</th><th align="left">%</th><th align="left">
<italic>n</italic>
</th><th align="left">%</th><th align="left">
<italic>n</italic>
</th><th align="left">%</th><th align="left">
<italic>n</italic>
</th><th align="left">%</th></tr></thead><tbody><tr><td align="left" colspan="9">HER2</td></tr><tr><td align="left">&#x000a0;0</td><td char="." align="char">15</td><td char="." align="char">31.3</td><td char="." align="char">8</td><td char="." align="char">16.7</td><td char="." align="char">8</td><td char="." align="char">16.7</td><td char="." align="char">31</td><td char="." align="char">64.6</td></tr><tr><td align="left">&#x000a0;1+</td><td char="." align="char">2</td><td char="." align="char">4.2</td><td char="." align="char">2</td><td char="." align="char">4.2</td><td char="." align="char">5</td><td char="." align="char">10.4</td><td char="." align="char">9</td><td char="." align="char">18.8</td></tr><tr><td align="left">&#x000a0;2+, 3+</td><td char="." align="char">4</td><td char="." align="char">8.3</td><td char="." align="char">2</td><td char="." align="char">4.2</td><td char="." align="char">1</td><td char="." align="char">2.1</td><td char="." align="char">7</td><td char="." align="char">14.6</td></tr><tr><td align="left">Total</td><td char="." align="char">21</td><td char="." align="char">43.8</td><td char="." align="char">12</td><td char="." align="char">25.0</td><td char="." align="char">14</td><td char="." align="char">29.2</td><td char="." align="char">47<sup>a</sup>
</td><td char="." align="char">97.9</td></tr></tbody></table><table-wrap-foot><p>
<italic>EGFR</italic> epidermal growth factor receptor, <italic>n</italic> number of patients, <italic>HER2</italic> human EGFR-2</p><p>
<sup>a</sup>One sample was &#x0201c;not detected&#x0201d;</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Efficacy</title><p>A total of 77 patients (<italic>n</italic>&#x000a0;=&#x000a0;38 in the N-IRI group and <italic>n</italic>&#x000a0;=&#x000a0;39 in the IRI group) were evaluable for radiologic tumor responses by an Independent Efficacy Evaluation Committee. PFS evaluated at 6&#x000a0;months after registration of the last patient was not significantly different between the treatment groups [median (95&#x000a0;% CI), 73.0 (55.0&#x02013;112.0) days in the N-IRI group vs. 85.0 (37.0&#x02013;93.0) days in the IRI group; HR (95&#x000a0;% CI), 0.860 (0.516&#x02013;1.435), <italic>P</italic>&#x000a0;=&#x000a0;0.5668] (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). 
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Kaplan&#x02013;Meier estimates of progression-free survival (<bold>a</bold>) and overall survival (<bold>b</bold>). <italic>N-IRI</italic> nimotuzumab plus irinotecan, <italic>IRI</italic> irinotecan alone</p></caption><graphic xlink:href="10120_2014_420_Fig2_HTML" id="MO2"/></fig></p><p>By 18&#x000a0;months after registration of the last patient, 34 patients from each group had died and the 18-month OS was not significantly different between the treatment groups [median (95&#x000a0;% CI), 250.5 (171.0&#x02013;306.0) days in the N-IRI group vs. 232.0 (148.0&#x02013;319.0) days in the IRI group; HR (95&#x000a0;% CI), 0.994 (0.618&#x02013;1.599), <italic>P</italic>&#x000a0;=&#x000a0;0.9778]. There was no significant difference in RR or DCR at the 18-month follow-up between the treatment groups (RR, 18.4&#x000a0;% in the N-IRI group vs. 10.3&#x000a0;% in the IRI group, <italic>P</italic>&#x000a0;=&#x000a0;0.3060; DCR, 47.4&#x000a0;% in the N-IRI group vs. 46.2&#x000a0;% in the IRI group, <italic>P</italic>&#x000a0;=&#x000a0;0.9150).</p><p>PFS and OS in the various subgroups analyzed were not significantly different between the treatment groups (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). However, the HR (IRI/N-IRI) in the EGFR 2+/3+ subgroup was lower than that in the entire treatment group. First, the median PFS (95&#x000a0;% CI) was 118.5 (87.0&#x02013;not estimated) days for six patients in the N-IRI group vs. 59.0 (24.0&#x02013;113.0) days for six patients in the IRI group [HR (95&#x000a0;% CI), 0.341 (0.080&#x02013;1.457), <italic>P</italic>&#x000a0;=&#x000a0;0.1293] (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Second, the median OS (95&#x000a0;% CI) was 358.5 (274.0&#x02013;458.0) days for six patients in the N-IRI group vs. 229.5 (58.0&#x02013;387.0) days for eight patients in the IRI group [HR (95&#x000a0;% CI), 0.369 (0.110&#x02013;1.242), <italic>P</italic>&#x000a0;=&#x000a0;0.0944] (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Furthermore, at the 18-month follow-up, the RR in the EGFR 2+/3+ subgroup was 33.3&#x000a0;% for six patients in the N-IRI group vs. 0.0&#x000a0;% for six patients in the IRI group, and the DCR in the corresponding groups was 83.3&#x000a0;% and 33.3&#x000a0;%, respectively. 
<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Subset forest plots for progression-free survival (<bold>a</bold>) and overall survival (<bold>b</bold>). <italic>N-IRI</italic> nimotuzumab plus irinotecan, <italic>IRI</italic> irinotecan alone, <italic>EGFR</italic> epidermal growth factor receptor, <italic>IHC</italic> immunohistochemistry, <italic>ECOG</italic> Eastern Cooperative Oncology Group, <italic>PS</italic> performance status</p></caption><graphic xlink:href="10120_2014_420_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec11"><title>Pharmacokinetics</title><p>Pharmacokinetic analysis was conducted using data collected from 11 patients (<italic>n</italic>&#x000a0;=&#x000a0;6 from the N-IRI group and <italic>n</italic>&#x000a0;=&#x000a0;5 from the IRI group). The pharmacokinetic parameters of nimotuzumab were similar to those reported from a previous phase I study of nimotuzumab in Japanese patients with solid tumors [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec12"><title>Safety</title><p>Adverse events were reported in all the patients. Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows the incidence, by treatment group, of major adverse events occurring at a frequency of &#x02265;15&#x000a0;% in at least one group. The most common adverse events (&#x02265;50&#x000a0;% in at least one group) were neutropenia, diarrhea, nausea, alopecia, decreased appetite, fatigue, and leukopenia. A rash occurred in 25.0&#x000a0;% (10/40) and 4.8&#x000a0;% (2/42) of patients in the N-IRI and IRI groups, respectively. There were no cases with severe (&#x02265;grade 3) skin toxicity, including severe rash. Grade 3 or higher adverse events were encountered in 77.5&#x000a0;% of patients in the N-IRI group and 64.3&#x000a0;% of patients in the IRI group. The most common grade 3 or higher adverse events (&#x02265;10&#x000a0;% in at least one group) were neutropenia, nausea, leukopenia, anemia, pneumonia, and decreased hemoglobin. The two pneumonia-related deaths in the N-IRI group were considered to be causally related to the study drug. All patients with pneumonia were evaluated by an Independent Data Monitoring Committee to detect pneumonitis. However, no cases of pneumonitis were identified. 
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Adverse events occurring at an incidence of&#x000a0;&#x02265;&#x000a0;15&#x000a0;% in each treatment arm</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Adverse event</th><th align="left" colspan="4">N-IRI (<italic>n</italic>&#x000a0;=&#x000a0;40)</th><th align="left" colspan="4">IRI (<italic>n</italic>&#x000a0;=&#x000a0;42)</th></tr><tr><th align="left" colspan="2">All grades</th><th align="left" colspan="2">&#x02265;Grade 3</th><th align="left" colspan="2">All grades</th><th align="left" colspan="2">&#x02265;Grade 3</th></tr><tr><th align="left">
<italic>n</italic>
</th><th align="left">%</th><th align="left">
<italic>n</italic>
</th><th align="left">%</th><th align="left">
<italic>n</italic>
</th><th align="left">%</th><th align="left">
<italic>n</italic>
</th><th align="left">%</th></tr></thead><tbody><tr><td align="left" colspan="9">Infections and infestations</td></tr><tr><td align="left">&#x000a0;Pneumonia</td><td align="left">8</td><td align="left">20.0</td><td align="left">4</td><td align="left">10.0</td><td align="left">1</td><td align="left">2.4</td><td align="left">0</td><td align="left">0.0</td></tr><tr><td align="left" colspan="9">Blood and lymphatic system disorders</td></tr><tr><td align="left">&#x000a0;Anemia</td><td align="left">7</td><td align="left">17.5</td><td align="left">5</td><td align="left">12.5</td><td align="left">4</td><td align="left">9.5</td><td align="left">3</td><td align="left">7.1</td></tr><tr><td align="left">&#x000a0;Leukopenia</td><td align="left">20</td><td align="left">50.0</td><td align="left">6</td><td align="left">15.0</td><td align="left">15</td><td align="left">35.7</td><td align="left">4</td><td align="left">9.5</td></tr><tr><td align="left">&#x000a0;Lymphopenia</td><td align="left">7</td><td align="left">17.5</td><td align="left">3</td><td align="left">7.5</td><td align="left">4</td><td align="left">9.5</td><td align="left">0</td><td align="left">0.0</td></tr><tr><td align="left">&#x000a0;Neutropenia</td><td align="left">29</td><td align="left">72.5</td><td align="left">18</td><td align="left">45.0</td><td align="left">23</td><td align="left">54.8</td><td align="left">16</td><td align="left">38.1</td></tr><tr><td align="left">&#x000a0;Thrombocytopenia</td><td align="left">1</td><td align="left">2.5</td><td align="left">0</td><td align="left">0.0</td><td align="left">7</td><td align="left">16.7</td><td align="left">3</td><td align="left">7.1</td></tr><tr><td align="left" colspan="9">Metabolism and nutrition disorders</td></tr><tr><td align="left">&#x000a0;Hypoalbuminemia</td><td align="left">7</td><td align="left">17.5</td><td align="left">0</td><td align="left">0.0</td><td align="left">5</td><td align="left">11.9</td><td align="left">1</td><td align="left">2.4</td></tr><tr><td align="left">&#x000a0;Decreased appetite</td><td align="left">22</td><td align="left">55.0</td><td align="left">3</td><td align="left">7.5</td><td align="left">26</td><td align="left">61.9</td><td align="left">3</td><td align="left">7.1</td></tr><tr><td align="left" colspan="9">Gastrointestinal disorders</td></tr><tr><td align="left">&#x000a0;Abdominal pain</td><td align="left">14</td><td align="left">35.0</td><td align="left">0</td><td align="left">0.0</td><td align="left">14</td><td align="left">33.3</td><td align="left">3</td><td align="left">7.1</td></tr><tr><td align="left">&#x000a0;Constipation</td><td align="left">12</td><td align="left">30.0</td><td align="left">0</td><td align="left">0.0</td><td align="left">12</td><td align="left">28.6</td><td align="left">0</td><td align="left">0.0</td></tr><tr><td align="left">&#x000a0;Diarrhea</td><td align="left">25</td><td align="left">62.5</td><td align="left">3</td><td align="left">7.5</td><td align="left">25</td><td align="left">59.5</td><td align="left">2</td><td align="left">4.8</td></tr><tr><td align="left">&#x000a0;Nausea</td><td align="left">25</td><td align="left">62.5</td><td align="left">6</td><td align="left">15.0</td><td align="left">25</td><td align="left">59.5</td><td align="left">4</td><td align="left">9.5</td></tr><tr><td align="left">&#x000a0;Stomatitis</td><td align="left">6</td><td align="left">15.0</td><td align="left">0</td><td align="left">0.0</td><td align="left">5</td><td align="left">11.9</td><td align="left">0</td><td align="left">0.0</td></tr><tr><td align="left">&#x000a0;Vomiting</td><td align="left">17</td><td align="left">42.5</td><td align="left">3</td><td align="left">7.5</td><td align="left">13</td><td align="left">31.0</td><td align="left">2</td><td align="left">4.8</td></tr><tr><td align="left" colspan="9">Skin and subcutaneous tissue disorders</td></tr><tr><td align="left">&#x000a0;Alopecia</td><td align="left">23</td><td align="left">57.5</td><td align="left">0</td><td align="left">0.0</td><td align="left">15</td><td align="left">35.7</td><td align="left">0</td><td align="left">0.0</td></tr><tr><td align="left">&#x000a0;Rash</td><td align="left">10</td><td align="left">25.0</td><td align="left">0</td><td align="left">0.0</td><td align="left">2</td><td align="left">4.8</td><td align="left">0</td><td align="left">0.0</td></tr><tr><td align="left" colspan="9">General disorders and administration site conditions</td></tr><tr><td align="left">&#x000a0;Asthenia</td><td align="left">7</td><td align="left">17.5</td><td align="left">1</td><td align="left">2.5</td><td align="left">9</td><td align="left">21.4</td><td align="left">1</td><td align="left">2.4</td></tr><tr><td align="left">&#x000a0;Fatigue</td><td align="left">21</td><td align="left">52.5</td><td align="left">3</td><td align="left">7.5</td><td align="left">15</td><td align="left">35.7</td><td align="left">3</td><td align="left">7.1</td></tr><tr><td align="left">&#x000a0;Pyrexia</td><td align="left">8</td><td align="left">20.0</td><td align="left">0</td><td align="left">0.0</td><td align="left">13</td><td align="left">31.0</td><td align="left">0</td><td align="left">0.0</td></tr><tr><td align="left" colspan="9">Investigations</td></tr><tr><td align="left">&#x000a0;Alanine aminotransferase increased</td><td align="left">8</td><td align="left">20.0</td><td align="left">1</td><td align="left">2.5</td><td align="left">6</td><td align="left">14.3</td><td align="left">1</td><td align="left">2.4</td></tr><tr><td align="left">&#x000a0;Aspartate aminotransferase increased</td><td align="left">7</td><td align="left">17.5</td><td align="left">1</td><td align="left">2.5</td><td align="left">7</td><td align="left">16.7</td><td align="left">1</td><td align="left">2.4</td></tr><tr><td align="left">&#x000a0;Hemoglobin decreased</td><td align="left">11</td><td align="left">27.5</td><td align="left">4</td><td align="left">10.0</td><td align="left">13</td><td align="left">31.0</td><td align="left">6</td><td align="left">14.3</td></tr><tr><td align="left">&#x000a0;Weight decreased</td><td align="left">12</td><td align="left">30.0</td><td align="left">2</td><td align="left">5.0</td><td align="left">8</td><td align="left">19.0</td><td align="left">0</td><td align="left">0.0</td></tr></tbody></table><table-wrap-foot><p>Number of patients, incidence of adverse events, and incidence of grades 3&#x02013;5 adverse events</p><p>
<italic>N</italic>-<italic>IRI</italic> nimotuzumab plus irinotecan, <italic>IRI</italic> irinotecan alone, <italic>n</italic> number of patients</p></table-wrap-foot></table-wrap></p><p>The incidence of adverse events resulting in discontinuation of irinotecan was 15.0&#x000a0;% (6/40) in the N-IRI group and 16.7&#x000a0;% (7/42) in the IRI group, with no significant difference between the two groups. The incidence of adverse events resulting in discontinuation of nimotuzumab was 7.5&#x000a0;% (3/40) in the N-IRI treatment group.</p><p>Adverse events were reported for all patients in the EGFR 2+/3+ subgroup, and no significant difference was found in the frequency of adverse events between the IRI and N-IRI groups in the EGFR 2+/3+ subgroup analysis. The incidence of adverse events in the EGFR 2+/3+ subgroup was similar to that in all randomized patients. In the EGFR 2+/3+ subgroup, rash of grade 1 or 2 occurred in 50.0&#x000a0;% (3/6) and 0.0&#x000a0;% (0/8) of patients in the N-IRI and IRI groups, respectively.</p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p>The primary endpoint of prolonged PFS was not achieved in this study, suggesting no significant benefit of N-IRI in non-biologically selected patients with AGC. This result is suggested by recent studies that evaluated the efficacy of anti-EGFR antibody administration to AGC patients who were not biologically selected. In two prospective randomized phase III studies (EXPAND, REAL-3) of cetuximab and panitumumab conducted in AGC patients, the primary endpoint could not be achieved [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. These negative results emphasize the need to identify the biological target before starting a large phase III study.</p><p>In a preclinical study, nimotuzumab showed marked antiproliferative, proapoptotic, and antiangiogenic effects against tumors showing EGFR overexpression [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. We previously demonstrated that the effects of nimotuzumab on human NSCLC cell lines were highly dependent on EGFR status [<xref ref-type="bibr" rid="CR28">28</xref>]. Nimotuzumab inhibited EGFR phosphorylation in cancer cells with high/moderate surface expression of EGFR, but not in those with low surface EGFR expression. Immunoblot analysis showed inhibition of EGFR phosphorylation in H292 and Ma-1 cells expressing high and moderate levels of EGFR on the cell surface, but not in H460, H1299, and H1975 cells showing a low level of surface EGFR expression [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p>In a clinical study of head and neck cancer to assess the efficacy of nimotuzumab in combination with radiotherapy, a controlled, double-blind, randomized clinical trial was conducted. For EGFR-positive patients, a significant survival improvement was detected for nimotuzumab-treated patients (OS, 16.5&#x000a0;months) compared with the control group (OS, 7.2&#x000a0;months) [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>Nimotuzumab is a humanized IgG1 antibody-directed agent, meaning that EGFR should be considered as the first candidate for its biological target. In this study, subset analysis showed a median PFS of 118.5&#x000a0;days in the EGFR 2+/3+ subgroup of the N-IRI group and 59.0&#x000a0;days in the corresponding subgroup of the IRI group; the RR was 33.3&#x000a0;% and 0.0&#x000a0;%, respectively. Furthermore, there was no significant difference in the frequency and seriousness of adverse events between the IRI and N-IRI groups in the subset of EGFR 2+/3+ subgroup analysis. Submission of tissue samples was not mandatory, and EGFR protein expression was only detected for 57.3&#x000a0;% of the full analysis set population. Therefore, the subset analysis based on the EGFR status could not yield any conclusive results. However, the results seem to imply that nimotuzumab can improve PFS and OS in AGC patients with high EGFR expression levels (2+/3+) when administered in combination with irinotecan.</p><p>In our study, the further exploratory biomarker of <italic>K-ras</italic> mutations was measured in 48 patients, and only 2 patients were found to harbor <italic>K-ras</italic> mutations. The <italic>EGFR</italic> gene copy number was measured in 46 patients, and 1 patient was detected with gene amplification. These results were consistent with previous reports [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The roles of <italic>K-ras</italic> mutations and <italic>EGFR</italic> gene amplification were not clear in this study.</p><p>Recently, the ToGA study showed that the HER-2-targeting monoclonal antibody trastuzumab improved OS in AGC patients with HER-2 protein overexpression by IHC or gene amplification by FISH [<xref ref-type="bibr" rid="CR10">10</xref>]. We also investigated the HER-2 expression levels by IHC and found that 14.6&#x000a0;% (7/48) of patients showed HER-2 2+/3+ expression and 29.2&#x000a0;% (14/48) of patients showed EGFR 2+/3+ expression. Only 2.1&#x000a0;% (1/48) of patients showed 2+/3+ expression of both EGFR and HER-2, suggesting there is little overlap between EGFR and HER-2 overexpression in gastric cancer [<xref ref-type="bibr" rid="CR13">13</xref>]. Currently, targeted therapy for gastric cancer is limited to patients with HER-2 overexpression. However, in future, patients with gastric cancer showing EGFR overexpression might benefit from treatment with nimotuzumab.</p><p>In the present study, rash occurred in ten patients (25.0&#x000a0;%) in the N-IRI group, which represents a lower frequency than that reported for patients receiving other anti-EGFR monoclonal antibodies, such as cetuximab or panitumumab [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Furthermore, there were no cases of severe (&#x02265;grade 3) skin toxicity in either treatment group. The frequency and severity of skin toxicity associated with nimotuzumab appears to be lower than that associated with other anti-EGFR antibodies. The safety profile of nimotuzumab could be expected to maintain good quality of life as well as compliance and shows potential for combination of nimotuzumab with irinotecan. The median relative dose intensity of irinotecan and nimotuzumab was 94.94&#x000a0;% and 96.55&#x000a0;%, respectively, in the N-IRI group. In the study of REAL-3, compliance with the baseline chemotherapy was decreased because of some severe toxicities, and the combination of a triple-chemotherapy regimen with panitumumab appears to be difficult to deliver [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>The mechanism underlying this lower frequency of skin toxicity of nimotuzumab compared with that of other known anti-EGFR antibodies has been investigated in several recent studies [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. These studies suggested that a low incidence of skin toxicity may be associated with the following: (1) the intermediate affinity (<italic>K</italic><sub>d</sub>&#x000a0;=&#x000a0;10<sup>&#x02212;8</sup>&#x000a0;M) of nimotuzumab, which is at least one order of magnitude lower than that of cetuximab or panitumumab; and (2) the different binding profile of nimotuzumab, which requires bivalent binding for stable attachment to the cellular surface compared with that of cetuximab, which requires only monovalent binding [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. This finding implies that nimotuzumab binding to EGFR occurs only when the surface EGFR density is sufficiently high to allow bivalent binding. Tumor cells overexpressing EGFR are common, allowing for selective binding of nimotuzumab.</p><p>In conclusion, although the primary endpoint of prolonged PFS was not met in our study, subset analysis showed that the N-IRI regimen may have potential to improve PFS and OS in EGFR 2+/3+ patients. An open-label, randomized phase III trial comparing N-IRI and IRI in EGFR 2+/3+ AGC patients is currently ongoing.</p></sec></body><back><fn-group><fn><p>Trial registration ID: JapicCTI-090849.</p></fn></fn-group><ack><p>We thank all the patients, their families, and the institutions involved in this study. The authors also thank the following individual board members for their contributions to this report: Independent Data Monitoring Committee, Keiichi Nagao, Noriyuki Masuda, Ichinosuke Hyodo, Baek-Yeol Ryoo, Young Iee Park, and Hong Suk Song; Efficacy Evaluation Committee, Atsushi Sato, Junji Tanaka, and Dae Young Zang; and Medical Advisors, Yutaka Ariyoshi and Kiyohiko Hatake. This trial was supported by a grant from Daiichi Sankyo Co., Ltd., Japan, and Kuhnil Pharm. Co., Ltd., Republic of Korea.</p><sec id="d30e2612"><title>Conflict of interest</title><p>T. Satoh, Y. Komatsu, Y. Yamada, and M. Munakata received research funding and honoraria from Daiichi Sankyo. Y.H. Kim received research funding and an honorarium from Kuhnil Pharm. K. Yamaguchi, N. Fuse, T. Ura, and S. Saitoh received research funding from Daiichi Sankyo. H. Yasui and S. Morita received honoraria from Daiichi Sankyo. Y. Sasaki, K. Nishio, and Y. Sakata received research funding, honoraria, and expert testimony from Daiichi Sankyo. K.H. Lee, S.Y. Rha, S.H. Park, T.Y. Kim, and S.Y. Kim have no conflicts of interests to declare.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murad</surname><given-names>AM</given-names></name><name><surname>Santiago</surname><given-names>FF</given-names></name><name><surname>Petroianu</surname><given-names>A</given-names></name><name><surname>Rocha</surname><given-names>PR</given-names></name><name><surname>Rodrigues</surname><given-names>MA</given-names></name><name><surname>Rausch</surname><given-names>M</given-names></name></person-group><article-title>Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer</article-title><source>Cancer (Phila)</source><year>1993</year><volume>72</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19930701)72:1&#x0003c;37::AID-CNCR2820720109&#x0003e;3.0.CO;2-P</pub-id><pub-id pub-id-type="pmid">8508427</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Ekstr&#x000f6;m</surname><given-names>K</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Sj&#x000f6;d&#x000e9;n</surname><given-names>PO</given-names></name><name><surname>Haglund</surname><given-names>U</given-names></name><etal/></person-group><article-title>Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer</article-title><source>Ann Oncol</source><year>1997</year><volume>8</volume><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1023/A:1008243606668</pub-id><pub-id pub-id-type="pmid">9093725</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>AD</given-names></name><name><surname>Grothe</surname><given-names>W</given-names></name><name><surname>Haerting</surname><given-names>J</given-names></name><name><surname>Kleber</surname><given-names>G</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Fleig</surname><given-names>WE</given-names></name></person-group><article-title>Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>2903</fpage><lpage>2909</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.05.0245</pub-id><pub-id pub-id-type="pmid">16782930</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Starling</surname><given-names>N</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Coxon</surname><given-names>F</given-names></name><etal/></person-group><article-title>Capecitabine and oxaliplatin for advanced esophagogastric cancer</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>36</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa073149</pub-id><pub-id pub-id-type="pmid">18172173</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial</article-title><source>Ann Oncol</source><year>2009</year><volume>20</volume><fpage>666</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdn717</pub-id><pub-id pub-id-type="pmid">19153121</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koizumi</surname><given-names>W</given-names></name><name><surname>Narahara</surname><given-names>H</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Takagane</surname><given-names>A</given-names></name><name><surname>Akiya</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>M</given-names></name><etal/></person-group><article-title>S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial</article-title><source>Lancet Oncol</source><year>2008</year><volume>9</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(08)70035-4</pub-id><pub-id pub-id-type="pmid">18282805</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Moiseyenko</surname><given-names>VM</given-names></name><name><surname>Tjulandin</surname><given-names>S</given-names></name><name><surname>Majlis</surname><given-names>A</given-names></name><name><surname>Constenla</surname><given-names>M</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><etal/></person-group><article-title>Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>4991</fpage><lpage>4997</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.06.8429</pub-id><pub-id pub-id-type="pmid">17075117</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thuss-Patience</surname><given-names>PC</given-names></name><name><surname>Kretzschmar</surname><given-names>A</given-names></name><name><surname>Bichev</surname><given-names>D</given-names></name><name><surname>Deist</surname><given-names>T</given-names></name><name><surname>Hinke</surname><given-names>A</given-names></name><name><surname>Breithaupt</surname><given-names>K</given-names></name><etal/></person-group><article-title>Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)</article-title><source>Eur J Cancer</source><year>2011</year><volume>47</volume><fpage>2306</fpage><lpage>2314</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2011.06.002</pub-id><pub-id pub-id-type="pmid">21742485</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>SI</given-names></name><name><surname>Lim</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>KW</given-names></name><name><surname>Oh</surname><given-names>SY</given-names></name><name><surname>Kwon</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>1513</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.39.4585</pub-id><pub-id pub-id-type="pmid">22412140</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Feyereislova</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Sawaki</surname><given-names>A</given-names></name><etal/></person-group><article-title>Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><fpage>687</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61121-X</pub-id><pub-id pub-id-type="pmid">20728210</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salomon</surname><given-names>DS</given-names></name><name><surname>Brandt</surname><given-names>R</given-names></name><name><surname>Ciardiello</surname><given-names>F</given-names></name><name><surname>Normanno</surname><given-names>N</given-names></name></person-group><article-title>Epidermal growth factor-related peptides and their receptors in human malignancies</article-title><source>Crit Rev Oncol Hematol</source><year>1995</year><volume>19</volume><fpage>183</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/1040-8428(94)00144-I</pub-id><pub-id pub-id-type="pmid">7612182</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MA</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>HE</given-names></name><name><surname>Jeon</surname><given-names>YK</given-names></name><name><surname>Yang</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>WH</given-names></name></person-group><article-title>EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number</article-title><source>Histopathology (Oxf)</source><year>2008</year><volume>52</volume><fpage>738</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2559.2008.03021.x</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terashima</surname><given-names>M</given-names></name><name><surname>Kitada</surname><given-names>K</given-names></name><name><surname>Ochiai</surname><given-names>A</given-names></name><name><surname>Ichikawa</surname><given-names>W</given-names></name><name><surname>Kurahashi</surname><given-names>I</given-names></name><name><surname>Sakuramoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of human epidermal growth factor receptor EGFR and ERBB2 on survival in stage II/III gastric cancer</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><issue>21</issue><fpage>5992</fpage><lpage>6000</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1318</pub-id><pub-id pub-id-type="pmid">22977193</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crombet-Ramos</surname><given-names>T</given-names></name><name><surname>Rak</surname><given-names>J</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>R</given-names></name><name><surname>Viloria-Petit</surname><given-names>A</given-names></name></person-group><article-title>Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody</article-title><source>Int J Cancer</source><year>2001</year><volume>101</volume><fpage>567</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1002/ijc.10647</pub-id><pub-id pub-id-type="pmid">12237899</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talavera</surname><given-names>A</given-names></name><name><surname>Friemann</surname><given-names>R</given-names></name><name><surname>G&#x000f3;mez-Puerta</surname><given-names>S</given-names></name><name><surname>Martinez-Fleites</surname><given-names>C</given-names></name><name><surname>Garrido</surname><given-names>G</given-names></name><name><surname>Rabasa</surname><given-names>A</given-names></name><etal/></person-group><article-title>Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>5851</fpage><lpage>5859</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4518</pub-id><pub-id pub-id-type="pmid">19584289</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido</surname><given-names>G</given-names></name><name><surname>Tikhomirov</surname><given-names>IA</given-names></name><name><surname>Rabasa</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>E</given-names></name><name><surname>Gracia</surname><given-names>E</given-names></name><name><surname>Iznaga</surname><given-names>N</given-names></name><etal/></person-group><article-title>Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile</article-title><source>Cancer Biol Ther</source><year>2011</year><volume>11</volume><fpage>373</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.4161/cbt.11.4.14097</pub-id><pub-id pub-id-type="pmid">21150278</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crombet</surname><given-names>T</given-names></name><name><surname>Torres</surname><given-names>L</given-names></name><name><surname>Neninger</surname><given-names>E</given-names></name><name><surname>Catal&#x000e1;</surname><given-names>M</given-names></name><name><surname>Solano</surname><given-names>ME</given-names></name><name><surname>Perera</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer</article-title><source>J Immunother</source><year>2003</year><volume>26</volume><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1097/00002371-200303000-00006</pub-id><pub-id pub-id-type="pmid">12616105</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>W</given-names></name><name><surname>Yoshino</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name><name><surname>Ueda</surname><given-names>S</given-names></name><name><surname>Tsuya</surname><given-names>A</given-names></name><etal/></person-group><article-title>A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors</article-title><source>Cancer Chemother Pharmacol</source><year>2013</year><volume>72</volume><fpage>1063</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1007/s00280-013-2277-8</pub-id><pub-id pub-id-type="pmid">24046058</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crombet</surname><given-names>T</given-names></name><name><surname>Osorio</surname><given-names>M</given-names></name><name><surname>Cruz</surname><given-names>T</given-names></name><name><surname>Roca</surname><given-names>C</given-names></name><name><surname>del Castillo</surname><given-names>R</given-names></name><name><surname>Mon</surname><given-names>R</given-names></name><etal/></person-group><article-title>Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>1646</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.03.089</pub-id><pub-id pub-id-type="pmid">15117987</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>TC</given-names></name><name><surname>Figueredo</surname><given-names>J</given-names></name><name><surname>Catala</surname><given-names>M</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>S</given-names></name><name><surname>Selva</surname><given-names>JC</given-names></name><name><surname>Cruz</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial</article-title><source>Cancer Biol Ther</source><year>2006</year><volume>5</volume><fpage>375</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.4161/cbt.5.4.2522</pub-id><pub-id pub-id-type="pmid">16575203</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>NS</given-names></name><name><surname>Armin</surname><given-names>M</given-names></name></person-group><article-title>Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system</article-title><source>Cancer (Phila)</source><year>2001</year><volume>92</volume><fpage>1331</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(20010901)92:5&#x0003c;1331::AID-CNCR1455&#x0003e;3.0.CO;2-M</pub-id><pub-id pub-id-type="pmid">11571750</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappuzzo</surname><given-names>F</given-names></name><name><surname>Hirsch</surname><given-names>FR</given-names></name><name><surname>Rossi</surname><given-names>E</given-names></name><name><surname>Bartolini</surname><given-names>S</given-names></name><name><surname>Ceresoli</surname><given-names>GL</given-names></name><name><surname>Bemis</surname><given-names>L</given-names></name><etal/></person-group><article-title>Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>643</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1093/jnci/dji112</pub-id><pub-id pub-id-type="pmid">15870435</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>HG</given-names></name><name><surname>Yoon</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy</article-title><source>Jpn J Clin Oncol</source><year>2004</year><volume>34</volume><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyh006</pub-id><pub-id pub-id-type="pmid">15020657</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hironaka</surname><given-names>S</given-names></name><name><surname>Zenda</surname><given-names>S</given-names></name><name><surname>Boku</surname><given-names>N</given-names></name><name><surname>Fukutomi</surname><given-names>A</given-names></name><name><surname>Yoshino</surname><given-names>T</given-names></name><name><surname>Onozawa</surname><given-names>Y</given-names></name></person-group><article-title>Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer</article-title><source>Gastric Cancer</source><year>2006</year><volume>9</volume><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1007/s10120-005-0351-6</pub-id><pub-id pub-id-type="pmid">16557431</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodera</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Mochizuki</surname><given-names>Y</given-names></name><name><surname>Fujitake</surname><given-names>S</given-names></name><name><surname>Koshikawa</surname><given-names>K</given-names></name><name><surname>Kanyama</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study)</article-title><source>Anticancer Res</source><year>2007</year><volume>27</volume><fpage>2667</fpage><lpage>2671</lpage><pub-id pub-id-type="pmid">17695430</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lordick</surname><given-names>F</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Salman</surname><given-names>P</given-names></name><name><surname>Oh</surname><given-names>SC</given-names></name><name><surname>Bodoky</surname><given-names>G</given-names></name><etal/></person-group><article-title>Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><issue>6</issue><fpage>490</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70102-5</pub-id><pub-id pub-id-type="pmid">23594786</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waddell</surname><given-names>TS</given-names></name><name><surname>Chau</surname><given-names>I</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Gonzalez</surname><given-names>D</given-names></name><name><surname>Okines</surname><given-names>AF</given-names></name><name><surname>Okines</surname><given-names>C</given-names></name><etal/></person-group><article-title>Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><issue>6</issue><fpage>481</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70096-2</pub-id><pub-id pub-id-type="pmid">23594787</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akashi</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name><name><surname>Iwasa</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Hatashita</surname><given-names>E</given-names></name><etal/></person-group><article-title>Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status</article-title><source>Br J Cancer</source><year>2008</year><volume>98</volume><fpage>749</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604222</pub-id><pub-id pub-id-type="pmid">18253126</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez</surname><given-names>MO</given-names></name><name><surname>Rivero</surname><given-names>TC</given-names></name><name><surname>del Castillo Bahi</surname><given-names>R</given-names></name><name><surname>Muchuli</surname><given-names>CR</given-names></name><name><surname>Bilbao</surname><given-names>MA</given-names></name><name><surname>Vinageras</surname><given-names>EN</given-names></name><etal/></person-group><article-title>Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck</article-title><source>Cancer Biol Ther</source><year>2010</year><volume>9</volume><issue>5</issue><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.4161/cbt.9.5.10981</pub-id><pub-id pub-id-type="pmid">20448462</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Soung</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>WS</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><etal/></person-group><article-title>BRAF and KRAS mutations in stomach cancer</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>6942</fpage><lpage>6945</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206749</pub-id><pub-id pub-id-type="pmid">14534542</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MA</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>HE</given-names></name><name><surname>Jeon</surname><given-names>YK</given-names></name><name><surname>Yang</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>WH</given-names></name></person-group><article-title>EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number</article-title><source>Histopathology (Oxf)</source><year>2008</year><volume>52</volume><issue>6</issue><fpage>738</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2559.2008.03021.x</pub-id></element-citation></ref></ref-list></back></article>